Alkermes seeks to support research designed and conducted by independent clinicians and scientists through our Investigator Sponsored Studies (ISS) program.
ISS concepts related to our areas of interest are reviewed according to the schedule below. Alkermes may occasionally announce a Request for Proposals (RFP) for research in clinical areas where gaps in data have been identified. Submission deadlines for any RFP topics will be announced on this site.
The ISS research Alkermes supports must be based in the United States and is typically conducted by experienced researchers who have an established history of successfully completing research with independent funding.
Alkermes can provide its marketed products to the ISS programs it supports. In addition, there may be financial support available, but please note that study budgets cannot exceed $300,000 (inclusive of overhead).
If you intend to request only study drug from Alkermes and will be seeking funding from a different source, we strongly recommend you submit your request to Alkermes for review before submitting a funding request to any third party.
The following types of research are considered for submission to the ISS program:
|Submissions Due||Decision Date|
|January 31, 2023||March 2023|
|April 29, 2023||June 2023|
|August 31, 2023||October 2023|
2023 RFP Submission Deadline
April 15, 2023
Aripiprazole lauroxil (AL)
We are not currently accepting ISS submissions focusing on substance use disorders.
Early career investigators may also be interested in the Alkermes Pathways Research Awards®, our annual research grant program that is designed to support the next generation of researchers who are focused on schizophrenia or bipolar I disorder.